The effects of semaglutide: what they are and how to weigh them up

The effects most people are actually deciding about

The question a lot of people bring to their first consultation is not really 'does semaglutide work?' It is closer to: 'Will I be able to cope with the side effects, and are the benefits worth it?' That is a fair framing, and it is worth taking seriously rather than glossing over.

On the benefit side, the STEP 1 trial published in the New England Journal of Medicine found an average weight reduction of around 15% over 68 weeks at the 2.4mg weekly dose alongside lifestyle changes. That is a meaningful shift for most people, and it happens because semaglutide changes the signals the brain receives about hunger and fullness, not through willpower, but through pharmacology.

On the side-effect side, the picture is mostly gastrointestinal: nausea, loose stools, constipation, indigestion, burping, and sometimes fatigue or headache. For many people these are most noticeable in the first week or two of treatment, or for a short period after a dose increase, then they ease. Some people do not experience them at all. A smaller number find them persistent enough to slow their titration schedule, which is exactly what the gradual dosing approach is designed to accommodate. You can read more about how semaglutide acts across the body on our effects of semaglutide on the body page.

The injection form (Wegovy) and the newer oral tablet follow similar side-effect profiles, though the pill's GI rates in the OASIS 4 trial were slightly higher, 74% of participants on the tablet reported some GI effect, the majority mild to moderate and transient.

The effects that need prompt medical attention

A question our prescribers hear most weeks is some version of: 'How do I know if a side effect is serious?' It is a good question, and the honest answer is that most of what people experience is uncomfortable rather than dangerous. But there are exceptions.

In January 2026 the MHRA issued a Drug Safety Update confirming that acute pancreatitis is a recognised (though infrequent) risk with GLP-1 medicines including semaglutide. The warning sign to act on is severe, persistent stomach pain that spreads to the back, particularly if it comes with vomiting. That is a reason to seek urgent medical help and to stop the medicine until you have been assessed.

Other effects worth telling a prescriber about promptly include: signs of a gallbladder problem (upper-right abdominal pain, especially after eating); dehydration from persistent vomiting or diarrhoea that you cannot manage with fluids; and any allergic reaction such as significant swelling, rash or breathing difficulty. Low mood or thoughts of self-harm should also prompt immediate contact with a healthcare professional.

If you experience something you are unsure about, you can report suspected side effects directly to the MHRA via the Yellow Card scheme. That reporting system also accepts reports about suspect or counterfeit products, which matters when buying any prescription medicine online. For a fuller picture of adverse effects, our guide to the adverse effects of semaglutide goes into more detail.

How long it takes to notice semaglutide's effects

Timing is one of the things people find hard to calibrate, partly because the answer genuinely varies. Appetite suppression tends to be the first thing people notice, sometimes within the first few days, more often by the end of the first or second week. Weight change follows more slowly, typically becoming measurable over the first month and building over several months as the dose increases.

The first dose of Wegovy is 0.25mg, which is a tolerability step: its job is to let the body adjust before the dose moves upward. Some people feel very little change at that level and worry the medicine is not working. That is normal. The treatment gains momentum as the dose titrates toward 1.7mg and then 2.4mg, or, for the newer 7.2mg single-dose pen approved by the MHRA in April 2026, potentially further still.

After stopping semaglutide, appetite typically returns and weight tends to come back without ongoing lifestyle support. There is a whole topic to explore here, our page on semaglutide after-effects covers what to expect once treatment ends. The timing of semaglutide's effects page also unpacks the week-by-week picture in more detail.

What shapes whether the effects are right for you

Semaglutide is licensed for adults with a BMI of 30 or above, or 27 or above where a weight-related condition such as high blood pressure, type 2 diabetes or sleep apnoea is present. Lower thresholds can apply for some ethnic backgrounds under UK clinical guidance. A BMI number alone does not determine suitability, a prescriber looks at your full medical history, current medicines, and whether there are any contraindications before anything is prescribed.

It is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive. It is not licensed for under-18s. Certain conditions (including a history of medullary thyroid carcinoma or pancreatitis) require careful prescriber discussion before treatment can be considered.

The semaglutide overview page covers eligibility and what the treatment programme involves in full. If you are looking specifically at cost (which is a reasonable thing to think about) our Wegovy pricing page explains what private treatment typically involves in the UK. And if you are ready to find out whether this is a clinically appropriate route for you, you can check your eligibility with our prescribers through a free consultation.